共 134 条
[31]
Liao CT(2010)Reirradiation of locally recurrent nasopharynx Cancer with external beam radiotherapy with or without brachytherapy Int J Radiat Oncol Biol Phys 76 130-2391
[32]
Chua DT(2015)Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities Transl Lung Cancer Res 4 560-1212
[33]
Sham JS(2016)Management of adverse events following treatment with anti-programmed death-1 agents Oncologist 21 1230-1341
[34]
Hung KN(2015)Toxicities of the anti-pd-1 and anti-pd-l1 immune checkpoint antibodies Ann Oncol 26 2375-W1000
[35]
Widesott L(2015)Pembrolizumab cutaneous adverse events and their association with disease progression JAMA Dermatol 151 1206-894
[36]
Pierelli A(2015)Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy JAMA Oncol 1 1340-7422
[37]
Fiorino C(2011)Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-ctla-4 antibody therapy AJR Am J Roentgenol 197 W992-355
[38]
Choy D(2016)Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes Clin Cancer Res 22 886-377
[39]
Sham JS(2015)In situ vaccination by radiotherapy to improve responses to anti-ctla-4 treatment Vaccine 33 7415-903
[40]
Wei WI(2017)Barriers to radiation-induced in situ tumor vaccination Front Immunol 8 229-510